S
Shinobi Therapeutics
0 followers
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
Org chart
Dan Kemp
Chief Executive Officer
Dan Kemp
Collapse
Bhanu Iyer
VP US Operations & HR
Ryosuke Gonotsubo
Chief Of Staff
Tobias Deuse
Co-founder
Molly Cole
Head Of BD And R&d Strategy
Teams
This company has no teams yet